Skip to main content
. Author manuscript; available in PMC: 2018 Aug 2.
Published in final edited form as: Leukemia. 2018 Feb 2;32(7):1575–1586. doi: 10.1038/s41375-018-0016-1

Figure 7. Clonally-derived SIPs convert to serially transplantable HSC after transplantation into fetal sheep.

Figure 7

(a) Percentage of total human hematopoietic (myeloid and lymphoid) engraftment at 75 days post-transplantation in animals transplanted with clonally-derived SIPs (n=8); each mark represents levels of engraftment within one animal. (b) Clonally-derived SIPs generated HSC with multilineage differentiation capability in primary and secondary recipients; overall percentage of engraftment within the different hematopoietic lineages. (c) HSC generated from clonally-derived SIPs are serially transplantable; human hematopoietic engraftment in blood and marrow in secondary animals (n=12), as determined by the percentage of human myeloid and lymphoid cells at 2 months post-transplant.